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bstract
An increased incidence of acute myeloid leukemia (AML) has recently been documented in patients post-solid organ transplantation but
he incidence and types of myelodysplastic syndromes (MDS) occurring in this patient population are not known. We identified 5 patients
3M, 2F, age 48–64 years) who developed MDS ranging from 1.8 to 25 years (median 4.2 years) post-solid organ transplantation, only 2
atients had received azathioprine. The cumulative incidence of MDS in heart and lung transplant recipients at 15 years was 0.5% and 1.8%,
espectively, which is markedly higher compared to the general population. Low-risk types of MDS predominated, 3 of 5 patients are alive
median 3.9 years) since diagnosis. Deletions of chromosome 20q, which have not been previously reported in post-transplant MDS/AML,
ere identified in 3 cases. Our findings expand the morphologic and cytogenetic spectrum of MDS occurring post-solid organ transplantation
nd suggest that mechanisms beside azathioprine toxicity might be important in disease pathogenesis.
2006 Elsevier Ltd. All rights reserved.












Myelodysplastic syndromes (MDS) are clonal hematopoi-
tic stem cell disorders characterized by dysplastic matu-
ation of one or more cell lineages leading to ineffective
ematopoiesis, peripheral cytopenias and an increased risk
f acute myeloid leukemia (AML) [1]. These disorders com-
only occur in patients over the age of 60 [2]. The crude inci-
ence of MDS is approximately 3.0/100,000 persons/year,
hich rises to 15–50/100,000 persons/year for individuals
ver 70 years of age [2,3]. The etiology of MDS remains
nclear but genetic insults, either inherited, e.g. Down syn-
rome and Fanconi anemia or acquired, the latter due to
nvironmental exposure to toxins, radiation, or cytotoxic
rugs, are thought to play important pathogenic roles [4,5].
∗ Corresponding author. Tel.: +1 212 342 1323; fax: +1 212 305 2301.







145-2126/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
oi:10.1016/j.leukres.2006.05.010rimary (de novo) and secondary forms of MDS are recog-
ized, the latter commonly related to prior chemotherapy [6].
hromosomal deletions, either complete or partial, involving
hromosomes 5, 7, 20, 11 and 13 are the most commonly
bserved cytogenetic abnormalities in MDS [7] and a few
f these have been linked to prior treatment with particular
hemotherapeutic agents, e.g. chromosome 5 and 7 abnor-
alities following treatment with alkylating agents and bal-
nced translocations of 11q23 (MLL) as a consequence of
opoisomerase II inhibitor therapy [6,8,9].
Acute leukemias and MDS occurring in recipients of solid
rgan transplants were either considered rare or thought to
ccur at rates similar to the general population [10–15]. How-
ver, recent studies have reported an increased risk of AML
n patients who have undergone solid organ transplantation,
hich has largely been attributed to azathioprine toxicity
10,11,16,17]. The incidence and etiology of MDS post-solid
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hioprine induced DNA damage has also been implicated
n the pathogenesis of these disorders [12,16,17]. Moreover,
ince chromosome 7 abnormalities are frequently observed
n AML/MDS following treatment with azathioprine, mech-
nisms similar to alkylating therapy-associated MDS are
hought to underlie MDS post-solid organ transplantation
18,19].
We undertook this study to determine the incidence, mor-
hologic spectrum, underlying cytogenetic abnormalities,
nd etiology of MDS post organ transplantation and assess
he clinical outcomes of patients diagnosed with these disor-
ers at our institute.
. Materials and methods
.1. Case identiﬁcation
A retrospective search of our histopathology database
as performed, over a 15-year period (1990–2004), to iden-
ify the number of bone marrow biopsy cases from patients
ost-solid organ transplantation. Results of clinical evalua-
ion and pertinent laboratory tests, including peripheral blood
ounts, were correlated with morphologic findings of bone
arrow biopsies to confirm the diagnosis of MDS. Biop-
ies from patients with a history of therapy for prior malig-
ancies were excluded from analysis. Information regarding
atient demographics, risk factors for MDS, underlying dis-
ase leading to transplantation, prior therapy and manage-
ent, organ type transplanted, and peripheral blood counts
prior to transplantation and at the time of diagnosis of
DS), was obtained from our clinical laboratory database
nd the treating physicians. The study was performed in
ccordance with the guidelines of our institutional review
oard.
.2. Morphologic evaluation, immunohistochemical
taining, and ﬂow cytometry
Hematoxylin-eosin (H&E) stained bone marrow biop-
ies were used for morphologic review in conjunction with
right-Giemsa and iron stained marrow aspirate smears
nd peripheral blood smears where available. All cases
ere classified according to the current WHO criteria [20].
mmunohistochemical (IHC) staining was performed on
ouins-fixed, paraffin-embedded bone marrow biopsy sec-
ions. Primary antibodies used included, CD34, CD117,
D61, myeloperoxidase (MPO), and glycophorin-A (DAKO,
arpinteria, CA), hMLH1 (BD Pharmingen, San Diego,
A), hMSH2 (Calbiochem, San Diego, CA), and hMSH6
Invitrogen, Carlsbad, CA). After moist heat induced anti-
en retrieval, using citrate buffer (pH 6.0) and low pH Tar-
et retrieval solution (DAKO) as applicable, the slides were
tained on an autostainer (universal staining system, DAKO)
sing the Envision Plus system (DAKO) for detection and
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arr virus early RNA (EBER; Ventana INFORM EBER,
ucson, AZ) was performed on all cases according to the
upplied protocol. Three or four-color flow cytometric anal-
sis (FACScan; Becton Dickinson, San Diego, CA, USA) was
erformed on the bone marrow aspirates or peripheral blood
sing the Cell Quest software (Becton Dickinson) according
o standard procedures. T-, B-, NK-cell, and myeloid lineage
pecific antigens were analyzed using a comprehensive panel
f monoclonal antibodies.
.3. Karyotype and ﬂuorescent in situ hybridization
FISH) analysis
Giemsa banding of metaphase preparations was per-
ormed using standard methods and the karyotypes were
escribed according to ISCN 1995 [21]. FISH analysis was
erformed on fixed cells with the EGR1/D5S23 and D20S108
robes (VYSIS, Downers Grove, IL, USA) using standard
rotocols; 200–500 cells were analyzed and fluorescence sig-
als were captured after counterstaining with DAPI using the
ytovision Imaging system attached to a Nikon Eclipse 600
icroscope (Applied Imaging, Santa Clara, CA, USA).
.4. Statistical analysis
The cumulative incidence of MDS for patients at risk was
alculated using the Kaplan–Meier (K–M) method with the
MDP release 7 software (BMDP statistical software Inc.,
niversity of California Press, CA).
. Results
.1. Prevalence and incidence of MDS post heart and
ung transplantation
A total of 1332 heart (age range 13 days–74 years) and
59 lung, including 31 combined heart and lung (age range
months–67 years) transplants were performed at our insti-
ute during the 15 year (1990–2004) study period. The period
revalence of MDS in heart and lung transplant recipients,
ombined, was 4/1691 (0.24%) and the crude incidence of
DS was 10/100,000/year and 37/100,000/year post heart
nd lung transplantation, respectively. However, the cumula-
ive incidence of MDS in heart and lung transplant recipients,
etermined by the K–M method, was 0.5% and 1.8% at 15
ears, respectively, which is higher compared to the crude
ncidence; 730 patients (501 post heart and 229 post lung
ransplantation) died and 115 patients (102 post heart and 13
ost lung transplantation) were lost to follow-up at variable
ime points during the study period (censored data). Standard-
zed incidence ratio and relative risk, as reported for AML
ost-transplantation [16,22], could not be calculated since
here are no national or regional data regarding the incidence
f MDS in the United States. The incidence of MDS post
enal transplantation could not be determined due to lack
M. Menes et al. / Leukemia Research 31 (2007) 59–65 61
Table 1


























Patient 2 48/F Kidneya Scleroderma 25a Cyclosporine
prednisone
azathioprine
RCMD A (8.3) 46,XX[8]/46,XX,del(20)(q11)[13]
Patient 3 53/M Bilateral lung UIP 1.8 Cyclosporine
prednisone
azathioprine
RA A (1.2) 46,XY,del(20)(q11)[2]/46,XY[19]
Patient 4 62/F Single lung UIP 3.2 Cyclosporine
mycophenolate
prednisone








RA LTF Not performed
Abbreviations: MDS, myelodysplastic syndrome; Dx, diagnosis; Tx, transplant; UIP, usual interstitial pneumonia; MPD, myeloproliferative disorder; U,


























































cTF, lost to follow-up.
a Patient underwent three successive kidney transplantations for membran
f follow-up care of many renal transplant patients at our
nstitution.
.2. Clinico-pathologic characteristics
Detailed clinical information, histologic findings, and
esults of cytogenetic analysis for each patient with MDS
re described below. In brief, 3 males and 2 females (age
ange 48–64 years, mean 57.4 years, median 60 years) who
ad undergone solid organ transplantation (heart [n = 2], lung
n = 2], and kidney [n = 1]) fulfilled the clinico-pathologic cri-
eria for MDS (Table 1). The marrow was hypercellular in 1,
ormocellular in 2, and hypocellular in 2 patients. Iron stores
ere either normal or increased and ringed sideroblasts were
ot identified. Loss of staining for DNA mismatch repair
MMR) proteins, hMLH1, hMSH2, and hMSH6 was not
bserved in any case, nuclear staining was observed in imma-
ure myeloid cells, monocytes, and rare megakaryocytes. ISH
or EBER was negative in all cases. None of the patients had
history of prior malignancy or hematological disorder but
ne patient had long-standing autoimmune disease (sclero-
erma). All patients had a normal CBC post-transplantation
nd were on maintenance immunosuppressive regimens with
ifferent drug combinations, only 2 had received azathioprine
Table 1). Median time from transplantation to diagnosis of
DS was 4.2 years (range 1.8–25 years, mean 7.7 years).
one of the patients received any therapy for MDS. Three of
patients are still alive with a median survival of 3.9 yearsost diagnosis (range 1.2–8.3 years, mean 4.5 years); includ-
ng 1 who developed T-lymphoblastic lymphoma (T-LBL).
ne patient developed AML 4 months post diagnosis and died
f infectious complications 2 months later, 1 patient was lost





Smerulonephritis, year of first transplant 1972.
.3. Patient 1
A 60-year-old man who underwent cardiac transplan-
ation in 1997 for ischemic cardiomyopathy was noted
o have an elevated WBC count (24.7 × 109/l), normo-
ytic normochromic anemia (Hgb 11), and thrombocy-
openia (94 × 109/l) on a routine examination in early
002. A bone marrow biopsy and aspirate showed hyper-
ellular marrow (90%) with mildly left shifted myeloid
yperplasia (M:E—8:1), and megakaryocytic hyperplasia
ith dysplasia, consistent with an unclassifiable myelodys-
lastic/myeloproliferative (MDS/MPD-U) disorder. Kary-
type analysis showed del(5)(q14q22). FISH analysis using
GR1/D5S23 probes showed a normal signal pattern, con-
rming that the cytogenetic deletion did not encompass
he EGR1 locus (5q31). His immunosuppressive regimen
ad consisted of prednisone, mycophenolate mofitil, and
yclosporine. The cumulative dose of cyclosporine received
rior to diagnosis of MDS/MPD was 330.7 g (175 mg/day
or 63 months, December 1997–February 2002). A few
onths post diagnosis he developed supraclavicular lym-
hadenopathy. An excisional biopsy revealed a precur-
or T-LBL that was CD4+ CD8+ (‘double positive’)
nd expressed CD56. PCR for TCR- gene rearrange-
ent showed a polyclonal product. Karyotype analysis
emonstrated del(5)(q14q22) suggesting a lymphoblastic
ransformation of his underlying MDS/MPD. He received
hemotherapy with cyclophosphamide, cytosine, cytara-
ine, methotrexate, and 6-mercaptopurine. Eight months
ater he developed splenomegaly and pancytopenia (WBC
.2 × 109/l). A repeat bone marrow biopsy and aspi-
ate showed findings similar to those observed previously.
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ive extramedullary hematopoiesis with left shifted myeloid
nd monocytic cells in the red pulp and rare blasts (<1%).
aryotype analysis revealed del(13)(q14) in addition, to
el(5)(q14q22). His last CBC (January 2005) showed mild
nemia (Hgb 11.5 g/dl), elevated WBC count (102 × 109/l),
ormal platelet count (172 × 109/l), and an absence of abso-
ute monocytosis. He is currently alive, 3.9 years since diag-
osis.
.4. Patient 2
A 48-year-old woman with long-standing scleroderma
nderwent cadaveric renal transplantation in 1972 for renal
ailure due to membranous glomerulonephritis and was re-
ransplanted twice, 4 and 15 years after her first transplant
the latter from a living related donor), for graft failure due to
hronic rejection. She was found to be anemic (Hgb 8.9)
ith an elevated MCV (121 fl) on routine examination in
997 but her WBC and platelet counts were within normal
ange. A bone marrow biopsy showed hypocellular mar-
ow (30%) with trilineage dysplasia and mild relative ery-
hroid hyperplasia with megaloblastic features (M:E—1:2),
onsistent with refractory cytopenia with multilineage dys-
lasia (RCMD). Karyotype analysis showed del(20)(q11).
er immunosuppressive regimen had consisted of azathio-
rine (50 mg/day for 40 months, June 1971–June 1996 and
00 mg for 13 months, July 1996–August 1997; cumulative
ose prior to diagnosis of MDS—480 g) and different combi-
ations of other drugs, including cyclosporine (200 mg/day
or 314 months, June 1971–August 1997; cumulative dose
884 g) and prednisone. She has undergone excisional skin
iopsies for multiple squamous cell and basal cell carcinomas
ut is currently alive 8.3 years since diagnosis of MDS. Her
ast CBC (October 2005) showed a mildly elevated WBC
ount (14.9 × 109/l), normal platelet count, and a normal
emoglobin level (14.8 g/dl) on maintenance erythropoietin
herapy.
.5. Patient 3
A 53-year-old man who had undergone bilateral lung
ransplantation in early 2002 for pulmonary failure due to
sual interstitial pneumonia (UIP) was found to have pancy-
openia (WBC 2.9 × 109/l, Hgb 10.1 g/dl and PLT 61 × 109/l)
nd an elevated MCV (105.6 fl) on routine follow-up exam
n late 2003. His past medical history was significant for
moking (1 pack/day) since the age of 16 and he had
orked for several years in the welding and sheet metal
anufacturing industry. Bone marrow biopsy and aspirate
n 2003 showed mildly hypocellular marrow (40%) and
oderate relative erythroid hyperplasia with megaloblastic
hange and dysplasia (M:E—1:3), consistent with refractory
nemia (RA). Karyotype analysis showed del(20)(q11) and
ISH with the D20S108 probe showed 7% of cells with
hromosome 20q deletion. His maintenance immunosup-
ression had consisted of cyclosporine (400 mg/day for 22
4
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onths, January 2002–October 2003; cumulative dose prior
o diagnosis of MDS—264 g), azathioprine (100 mg/day
or 15 months, October 2000–December 2001; cumulative
ose—45 g), and prednisone. He is currently alive 1.2 years
ince diagnosis. His last CBC (November, 2005) showed per-
istent anemia (Hgb 10.9 g/dl ) and normal WBC and platelet
ounts.
.6. Patient 4
A 62-year-old woman who had undergone a single lung
ransplant for UIP in 2001 presented with complaints of
ncreasing fatigue and malaise in mid 2004. Hematologic
ork up showed pancytopenia (WBC 2.9 × 109/l, Hgb
.2 g/dl, and PLT 42 × 109/l) and elevated MCV (112.4 fl).
one marrow biopsy and aspirate showed normocellular mar-
ow (50%) with left shifted myeloid maturation (M:E—3:1),
egaloblastic changes and dysplasia of the erythroid lin-
age, megakaryocytic dysplasia, and 6% blasts, consistent
ith refractory anemia with excess blasts-type 1 (RAEB-
). Blasts were also noted on the peripheral blood smear
nd had the following phenotype: CD34+, CD117+, CD13+,
nd MPO+. Cytogenetic analysis demonstrated a com-
lex karyotype including del(20)(q11.2), −5, and −13 (see
able 1). Her maintenance immunosuppression had consisted
f cyclosporine (300 mg/day for 39 months, April 2001–May
004; cumulative dose prior to diagnosis of MDS—351 g)
ycophenolate mofitil, and prednisone. Increased blasts
22%) were noted in the peripheral blood 4 months post
iagnosis, consistent with AML. She died of infectious com-
lications 2 months later.
.7. Patient 5
A 64-year-old man who had undergone a heart transplant
or ischemic cardiomyopathy in early 1990 presented with
paratracheal mass in 1994 that on biopsy showed a B-
ell, polymorphic, post-transplant lymphoproliferative disor-
er (PTLD). Hematologic work-up demonstrated macrocytic
nemia (Hgb 8.7 g/dl, MCV 102 fl) and his WBC and platelet
ounts were within normal range. A staging marrow biopsy
howed normocellular marrow (50%), mild absolute ery-
hroid hyperplasia (M:E—1:2) with megaloblastic features
nd dysplasia, consistent with RA. There was no evidence
f marrow involvement by lymphoma; cytogenetic analy-
is was not performed. His immunosuppressive regimen had
onsisted of cyclosporine (300 mg/day for 53 months, Jan-
ary 1990–May 1994; cumulative dose prior to diagnosis
f MDS—477 g) and prednisone. He was lost to follow-up
hortly after diagnosis.. Discussion
Recipients of solid organ transplants are at an increased
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ially lymphomas, as a consequence of prolonged therapeutic
mmunosuppression [23]. Acute leukemias, including AML
nd acute lymphoblastic leukemia (ALL), have been reported
o occur at variable time intervals post-solid organ transplan-
ation [10,11,15,16,22,25]. These malignancies were consid-
red sporadic events in the past, however, recent large single
nd multi-institutional studies have reported an increased
ncidence of AML post renal [16], liver [22], heart [11,16],
nd lung transplantation [16]. Moreover, the relative risk for
eveloping AML has been shown to be higher post heart
nd lung transplantation compared to renal transplantation
16]. Dysplastic hematopoiesis, commonly observed follow-
ng solid organ transplantation, is thought to have a multi-
actorial but non-neoplastic etiology [29]. Only a few reports
nd small case series have described MDS in recipients of
olid organ allografts [10–12,14,16,26–28,30–32], mostly in
ecipients of renal transplants. However, data regarding the
ncidence and morphogenetic spectrum of MDS post-solid
rgan transplantation are limited.
Our study is the first to provide data regarding the cumu-
ative incidence of MDS post heart and lung transplantation.
he cumulative incidence of MDS at 15 years was 0.5%
nd 1.8% post heart and lung transplantation, respectively,
hich is 2.6–9.5 and 9.5–34.3-fold higher than the inci-
ence of MDS reported for the general population [2,3].
he prevalence of MDS post heart and lung transplantation
t our institution (0.24%) is similar to that estimated from
he data of Huebner et al. [11] for heart transplant recipients
0.32%). The age at diagnosis of MDS of our patients is also
n accord with published observations that report a younger
ge (<50 years) for kidney transplant recipients compared
o patients post heart and lung transplantation (>60 years)
11,16,26–28]. A review of the literature, however, revealed
wide age range (28–72 years) of patients developing MDS
ost-solid organ transplantation [10–12,14,16,26–28,30–32],
hich is not dissimilar to that reported for individuals with
rimary MDS [1] or therapy-related MDS [33], includ-
ng those with MDS following thiopurine therapy for non-
eoplastic diseases [34].
A higher incidence of lower risk MDS (RA and RCMD)
as seen in our series that was associated with a longer
edian survival (3.9 years) although, evolution to AML and
-LBL occurred in one patient each. The survival time of
ur patients is within the range reported for young adults
ho have a higher prevalence of RA [35] but the median age
as similar to the population at risk for primary MDS [5].
ur findings are in contrast to the majority of previous stud-
es, which described high risk types of MDS with frequent
ransformation to AML and a poor prognosis [11,12,16,28].
ince most of the published studies either predated the WHO
lassification or used the FAB classification, cases described
s RAEB-T would now be considered AML [16,36]. Onlysingle case of refractory anemia with ringed siderob-
asts was described in the report by Offman et al. [16].
hronic myeloproliferative disorders, including CML, have
een described post-solid organ transplantation [24], how-
e
b
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ver, a MDS/MPD “overlap” disorder, as observed in one of
ur patients, could not be identified in a search of the English
iterature.
MDS in the majority of our patients were associated with
ormocellular or hypocellular marrow. Occasional cases of
ypocellular MDS have been reported post-solid organ trans-
lantation [16,26] but since most of the published reports did
ot quantify marrow cellularity, it is unclear if low cellularity
s a unique feature of MDS in the post-transplant setting.
ypoplasia of one or more hematopoietic lineages is not
ncommon in recipients of organ allografts. The underlying
echanisms are not well understood, however, immunosup-
ressive drug toxicity has been implicated in some cases
29,37,38]. Another interesting finding of our study, also
bserved by Clatch et al. [29] and Kim et al. [39], is the pre-
ominance of erythroid dyspoiesis, especially megaloblastic
hange in the absence of folate or Vitamin B12 deficiency.
zathioprine toxicity has been considered responsible for
his phenomenon [39] since megaloblastoid erythropoiesis is
lso seen in patients with collagen-vascular disease treated
ith azathioprine [40–43]. Although azathioprine therapy
ight have contributed to erythroid macrocytosis in a few
atients, we consider erythrocytic dysplasia to be a conse-
uence of the neoplastic process. Three of 4 patients who had
rythroid or erythroid and megakaryocytic dysplasia demon-
trated del(20q), an abnormality that has not been associated
ith azathioprine therapy. It is of interest to note that a pre-
ominance of erythroid and megakaryocytic dysplasia has
een described in MDS associated with del(20q), which has
een postulated to be due to loss of genes located on chro-
osome 20q that might be critical for megakaryocytic and
rythroid progenitor cell development or function [44].
The pathogenesis of post-transplant MDS is not well
nderstood but azathioprine toxicity has been considered an
mportant risk factor [16]. Chromosomal breaks and other
ytogenetic abnormalities have been observed in marrow
spirates from patients treated with azathioprine [45] and
pontaneous remission of RA associated with monosomy 7
as reported in a renal transplant patient upon discontin-
ation of azathioprine [27]. A whole host of cytogenetic
bnormalities, mostly numerical, have been described in
atients with MDS post-transplant, including del(1), −5, −7,
8, del(5q), del(6q), del(7q), del(9q), del(17p), −17, −18,
19, −20 and −21[11,12,16,32]. Many of these aberrations
re similar to those observed in therapy-related MDS [46],
hich lead to deregulation of multiple distinct genetic path-
ays [47]. A search of the literature did not yield any reports
f del(20q) in post-transplant MDS/AML. Chromosome 7
bnormalities, the most commonly reported cytogenetic aber-
ations in post-transplant MDS and alkylating therapy-related
DS, including cases associated with azathioprine therapy
16,27,30,31,46,48], were not detected in any of our patients.At the molecular level, defects in MMR, possibly due to
pigenetic silencing of enzymes mediating this process, have
een demonstrated in patients with post-transplant MDS [16]
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rugs) [16]. MMR defects have also been observed in other
orms of therapy-related MDS but not de novo MDS [49].
ndividuals with thiopurine methyltransferase (TPMT) poly-
orphisms, leading to low levels of this enzyme, are thought
o be at increased risk for developing MDS [50,51]. We per-
ormed staining for MMR proteins due to unavailability of
enomic DNA. Absence of staining, considered an indirect
arker for MMR deficient or microsatellite instability high
MSI+) neoplasms, was not observed in any case. Since stain-
ng for MMR proteins lacks sufficient sensitivity [52,53], our
ndings do not rule out the possibility of MMR deficiency in
ome of the cases.
Pre-transplant risk factors, cigarette smoking and long-
tanding autoimmune disease, could have contributed to the
evelopment of MDS in two of our patients. Autoimmune
echanisms have been proposed in the pathogenesis of at
east a subset of patients with MDS [54,55] and autoim-
une disorders, including SLE and Sjogrens syndrome, can
e observed in approximately 10% of MDS patients [55]. An
bsence of known risk factors in other patients, however, sug-
ests a role for immunosuppression in disease pathogenesis.
n increased incidence of MDS has been reported in pedi-
tric patients treated with cyclosporine for acquired aplas-
ic anemia [56,57]. Decreased immune surveillance could
otentially allow the survival of hematopoietic progenitors
hat incurred mutagenic insults either prior to or post organ
ransplantation.
In summary, we identified an increased incidence of MDS
n individuals post heart and lung transplantation. The major-
ty of our patients had low-risk types of MDS and, in contrast
o previous reports, del(20q) was the most common cyto-
enetic abnormality observed. Since the clinical course of
atients with MDS post organ transplantation can be rel-
tively indolent and the dysplastic changes often subtle,
ytogenetic analysis of bone marrow aspirates is critical in
he diagnostic evaluation of unexplained cytopenias in these
atients. The etiology of MDS post-solid organ transplan-
ation appears multifactorial but immunosuppression likely
lays an important role. Future large-scale genome analy-
es, similar to those employed in determining risk factors for
herapy-related AML [58], might help elucidate important
usceptibility factors for MDS/AML post-solid organ trans-
lantation.
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